Role of pericytes in angiogenesis: Focus on cancer angiogenesis and anti-angiogenic therapy

Neoplasma

Volumn 63, Issue 2, 2016, Pages 173-182

  Chen, Z ^a   Xu, X H ^a   Hu, J ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Angiogenesis; Cancer; Pericytes

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANGIOPOIETIN RECEPTOR; CHEMOKINE RECEPTOR CXCR4; GELATINASE B; HEPARAN SULFATE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSOPHOSPHATIDIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE CELL ADHESION MOLECULE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN ZO1; REGORAFENIB; SCATTER FACTOR; SEMAPHORIN; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; DOWN REGULATION; GLIOBLASTOMA; HUMAN; HYPOXIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPH VESSEL METASTASIS; NONHUMAN; OXYGENATION; PERICYTE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; CELL MOTION; ENDOTHELIUM CELL; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

CELL MOVEMENT; ENDOTHELIAL CELLS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES;

EID: 84969677830     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/201_150704N369     Document Type: Review

References (115)

1. DORE-DUFFY P, CLEARY K. Morphology and properties of pericytes. Methods Mol Biol 2011; 686: 49-68. http://dx.doi. org/10.1007/978-1-60761-938-3 2
2. ARMULIK A, GENOVE G, BETSHOLTZ C. pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011; 21: 193-215. http:// dx.doi.org/10.1016/j.devcel.2011.07.001
3. SIMONAVICIUS N, ASHENDEN M, VAN WEVERWIJK A, LAX S, HUSO DL et al. Pericytes promote selective vessel regression to regulate vascular patterning. Blood 2012; 120: 1516-1527. http://dx.doi.org/10.1182/blood-2011-01-332338
4. LIN J, LEMKE C, REDIES C, YAN X, MIX E et al. ADAM17 overexpression promotes angiogenesis by increasing blood vessel sprouting and pericyte number during brain microvessel development. Int J Dev Biol 2011; 55: 961-968. http:// dx.doi.org/10.1387/ijdb.103210jl
5. GORDON MS, MENDELSON DS, KATO G. Tumor angio-genesis and novel antiangiogenic strategies. Int J Cancer 2010; 126: 1777-1787. http://dx.doi.org/10.1002/ijc.25026
6. CHANG WG, ANDREJECSK JW, KLUGER MS, SALTZMAN WM, POBER JS. Pericytes modulate endothelial sprouting. Cardiovasc Res 2013; 100: 492-500. http://dx.doi. org/10.1093/cvr/cvt215
7. HALL CN, REYNELL C, GESSLEIN B, HAMILTON NB, MISHRA A et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 2014; 508: 55-60. http:// dx.doi.org/10.1038/nature13165
8. PROEBSTL D, VOISIN MB, WOODFIN A, WHITEFORD J, D'ACQUISTO F et al. Pericytes support neutrophil suben-dothelial cell crawling and breaching of venular walls in vivo. J Exp Med 2012; 209: 1219-1234. http://dx.doi.org/10.1084/ jem.20111622
9. BOSE A, BARIK S, BANERJEE S, GHOSH T, MALLICK A et al. Tumor-derived vascular pericytes anergize Th cells. J Immunol 2013; 191: 971-981. http://dx.doi.org/10.4049/ jimmunol.1300280
10. DALKARA T, ALARCON-MARTINEZ L. Cerebral micro-vascular pericytes and neurogliovascular signaling in health and disease. Brain Res 2015. http://dx.doi.org/10.1016/j. brainres.2015.03.047
11. CHATTERJEE S, NAIK UP. Pericyte-endothelial cell interaction: a survival mechanism for the tumor vasculature. Cell Adh Migr 2012; 6: 157-159. http://dx.doi.org/10.4161/ cam.20252
12. LUK K, BOATMAN S, JOHNSON KN, DUDEK OA, RISTAU N et al. Influence of morphine on pericyte-endothelial interaction: implications for antiangiogenic therapy. J Oncol 2012; 2012: 458385. http://dx.doi.org/10.1155/2012/458385
13. ZHOU H, YANG YH, BASILE JR. The Semaphorin 4D-Plexin-B1-RhoA signaling axis recruits pericytes and regulates vascular permeability through endothelial production of PDGF-B and ANGPTL4. Angiogenesis 2014; 17: 261-274. http://dx.doi.org/10.1007/s10456-013-9395-0
14. BERTHOD F, SYMES J, TREMBLAY N, MEDIN JA, AUGER FA. Spontaneous fibroblast derived pericyte recruitment in a human tissue-engineered angiogenesis model in vitro. J Cell Physiol 2012; 227: 2130-2137. http://dx.doi.org/10.1002/ icp.22943
15. RIBATTI D, NICO B, CRIVELLATO E. The role of pericytes in angiogenesis. Int J Dev Biol 2011; 55: 261-268. http://dx.doi. org/10.1387/ijdb.103167dr
16. STRATMAN AN, SCHWINDT AE, MALOTTE KM, DAVIS GE. Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood 2010; 116: 4720-4730. http:// dx.doi.org/10.1182/blood-2010-05-286872
17. GENOVE G, MOLLICK T, JOHANSSON K. Photoreceptor degeneration, structural remodeling and glial activation: a morphological study on a geneticmouse model for pericyte deficiency. Neuroscience 2014; 279: 269-284. http://dx.doi. org/10.1016/j.neuroscience.2014.09.013
18. SUNDBERG C, FRIMAN T, HECHT LE, KUHL C, SOLOMON KR. Two different PDGF beta-receptor cohorts in human pericytes mediate distinct biological endpoints. Am J Pathol 2009; 175: 171-189. http://dx.doi.org/10.2353/ aipath.2009.080769
19. SONG N, HUANG Y, SHI H, YUAN S, DING Y et al. Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/ CXCR4 axis. Cancer Res 2009; 69: 6057-6064. http://dx.doi. org/10.1158/0008-5472.CAN-08-2007
20. HAMDAN R, ZHOU Z, KLEINERMAN ES. Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors. Mol Cancer Ther 2014; 13: 483-491. http://dx.doi.org/10.1158/1535-7163.MCT-13-0447
21. DHAR K, DHAR G, MAJUMDER M, HAQUE I, MEHTA S et al. Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1. Mol Cancer 2010; 9: 209. http:// dx.doi.org/10.1186/1476-4598-9-209
22. ABRAMSSON A, KURUP S, BUSSE M, YAMADA S, LINDBLOM P et al. Defective N-sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment invascular development. Genes Dev 2007; 21: 316-331. http://dx.doi.org/10.1101/gad.398207
23. BUCHANAN CF, SZOT CS, WILSON TD, AKMAN S, METHENY-BARLOW LJ et al. Cross-talk between endothelial and breast cancer cells regulates reciprocal expression of angiogenic factors in vitro. J Cell Biochem 2012; 113: 1142-1151. http://dx.doi.org/10.1002/jcb.23447
24. CHAKROBORTY D, SARKAR C, YU H, WANG J, LIU Z et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci USA 2011; 108: 20730-5. http://dx.doi.org/10.1073/ pnas.1108696108
25. AUGUSTIN HG, KOH GY, THURSTON G, ALITALO K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10: 165-177. http://dx.doi.org/10.1038/nrm2639
26. GAENGEL K, GENOVE G, ARMULIK A, BETSHOLTZ C. Endothelial mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb Vasc Biol 2009; 29: 630-638. http://dx.doi.org/10.1161/ATVBAHA.107.161521
27. FUXE J, TABRUYN S, COLTON K, ZAID H, ADAMS A et al. Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. Am J Pathol 2011; 178: 2897-2909. http://dx.doi.org/10.1016/!. aipath.2011.02.008
28. KESKIN D, KIM J, COOKE VG, WU CC, SUGIMOTO H et al. Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Rep 2015; 10: 1066-1081. http://dx.doi.org/10.1016/j.celrep.2015.01.035
29. YU X, RADULESCU A, CHEN CL, JAMES IO, BESNER GE. Heparin-binding EGF-like growth factor protects pericytes from injury. J Surg Res 2012; 172: 165-176. http://dx.doi. org/10.1016/j.jss.2010.07.058
30. CHAE SS, KAMOUN WS, FARRAR CT, KIRKPATRICK ND, NIEMEYER E et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearinggliomas. Clin Cancer Res 2010; 16: 3618-3627. http://dx.doi.org/10.1158/1078-0432.CCR-09-3073
31. FAGIANI E, LORENTZ P, KOPFSTEIN L, CHRISTOFORI G. Angiopoietin-1 and-2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. Cancer Res 2011;71: 5717-5727. http://dx.doi.org/10.1158/0008-5472. CAN-10-4635
32. SEKI T, HONG KH, OH SP. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab Invest 2006; 86: 116-129. http:// dx.doi.org/10.1038/labinvest.3700376
33. THALGOTT J, DOS-SANTOS-LUIS D, LEBRIN F. Pericytes as targets in hereditary hemorrhagic telangiectasia. Front Genet 2015; 6: 37. http://dx.doi.org/10.3389/ fgene.2015.00037
34. VAN DER MEER AD, ORLOVA VV, TEN DIJKE P, VAN DEN BERG A, MUMMERY CL. Three-dimensional cocultures of human endothelial cells and embryonic stem cell-derived pericytes inside a microfluidic device. Lab Chip 2013; 13: 3562-3568. http://dx.doi.org/10.1039/c3lc50435b
35. SONG S, EWALD AJ, STALLCUP W, WERB Z, BERGERS G. PDGFRbeta(+) perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005; 7: 870-879. http://dx.doi.org/10.1038/ncb1288
36. ORLOVA VV, LIU Z, GOUMANS MJ, TEN DIJKE P. Controlling angiogenesis by two unique TGF-β type I receptor signaling pathways. Histol Histopathol 2011; 26: 1219-1230.
37. LEBRIN F, DECKERS M, BERTOLINO P, TEN DIJKE P. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005; 65: 599-608. http://dx.doi.org/10.1016/j. cardiores.2004.10.036
38. VAN GEEST RJ, KLAASSEN I, VOGELS IM, VAN NOORDEN CJ, SCHLINGEMANN RO. Differential TGF-{beta{ signaling in retinal vascular cells: a role in diabetic retinopathy?. Invest Ophthalmol vis Sci 2010; 51: 1857-1865. http://dx.doi.org/10.1167/iovs.09-4181
39. ZHU Q, KIM YH, WANG D, OH SP, LUO K. SnoN facilitates ALK1-Smad1/5 signaling during embryonic angiogenesis. J Cell Biol 2013; 202: 937-950. http://dx.doi.org/10.1083/ jcb.201208113
40. CHEN W, GUO Y, WALKER EJ, SHEN F, JUN K et al. Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain. Arterioscler Thromb Vasc Biol 2013; 33: 305-310. http://dx.doi. org/10.1161/ATVBAHA.112.300485
41. QIAN BZ, LI J, ZHANG H, KITAMURA T, ZHANG J et al. CCL2 recruits inflammatory monocytes to facilitate breast tumour metastasis. Nature 2011; 475: 222-225. http://dx.doi. org/10.1038/nature10138
42. HUANG C, DAY ML, PORONNIK P, POLLOCK CA, CHEN XM. Inhibition of KCa3.1 suppresses TGF-β1 induced MCP-1 expression in human proximal tubular cells through Smad3, p28 and ERK1/2 signaling pathways. Int J Biochem Cell Biol 2014; 47: 1-10. http://dx.doi.org/10.1016/j. biocel.2013.11.017
43. WILSON TJ, NANNURU KC, FUTAKUCHI M, SINGH RK. Cathepsin G-mediated enhanced TGF-beta signaling promotes angiogenesis via upregulation ofVEGF and MCP-1. Cancer Lett 2010; 288: 162-169. http://dx.doi.org/10.1016/j. canlet.2009.06.035
44. NAKAJIMA C, HAFFNER P, GOERKE SM, ZURHOVE K, ADELMANN G et al. The lipoprotein receptor LRP1 modulates sphingosine-1-phosphate signaling and is essential for vasculardevelopment. Development 2014; 141: 4513-4525. http://dx.doi.org/10.1242/dev.109124
45. MENDELSON K, ZYGMUNT T, TORRES-VAZQUEZ J, EVANS T, HLA T. Sphingosine 1-phosphate receptor signaling regulates proper embryonic vascular patterning. J Biol Chem 2013; 288: 2143-2156. http://dx.doi.org/10.1074/jbc. M112.427344
46. TAKABE K, YAMADA A, RASHID OM, ADAMS BJ, HUANG WC et al. Twofer anti-vascular therapy targeting sphingosine-1-phosphate for breast cancer. Gland Surg 2012; 1: 80-83.
47. TOBIA C, CHIODELLI P, NICOLI S, DELL'ERA P, BURASCHI S et al. Sphingosine-1-phosphate receptor-1 controls venous endothelial barrier integrity in zebrafish. Arterioscler Thromb Vasc Biol 2012; 32: e104-116. http://dx.doi. org/10.1161/ATVBAHA.112.250035
48. SCHUCHARDT M, TOLLE M, PRUFER J, VAN DER GIET M. Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system. Br J Pharmacol 2011; 163: 1140-62. http://dx.doi.org/10.1111/j.1476-5381.2011.01260.x
49. DU W, TAKUWA N, YOSHIOKA K, OKAMOTO Y, GONDA K et al. S1p(2), the g protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Res 2010; 70: 772-781. http://dx.doi.org/10.1158/0008-5472.CAN-09-2722
50. BEN SHOHAM A, MALKINSON G, KRIEF S, SHWARTZ Y, ELY Y et al. S1P1 inhibits sprouting angiogenesis during vascular development. Development 2012; 139: 3859-3869. http://dx.doi.org/10.1242/dev.078550
51. MACHIDA T, TAKATA F, MATSUMOTO J, TAKENOSHITA H, KIMURA I et al. Brain pericytes are the most thrombin-sensitive matrix metalloproteinase-9-releasing cell type constituting theblood-brain barrier in vitro. Neurosci Lett 2015; 599: 109-114. http://dx.doi.org/10.1016/j. neulet.2015.05.028
52. THANABALASUNDARAM G, SCHNEIDEWIND J. The impact of pericytes on the blood-brain barrier integrity depends critically on the pericyte differentiation stage. Int J Biochem Cell Biol 2011; 43: 1284-1293. http://dx.doi.org/10.1016/j. biocel.2011.05.002
53. TAKATA F, DOHGU S, MATSUMOTO J, TAKAHASHI H, MACHIDA T et al. Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-α, releasing matrix metalloproteinase-9 and migrating in vitro. J Neuroinflammation 2011; 8: 106. http://dx.doi. org/10.1186/1742-2094-8-106
54. TAKAHASHI Y, MAKI T, LIANG AC, ITOH K, LOK J et al. p38 MAP kinase mediates transforming-growth factor-1-induced upregulation of matrix metalloproteinase-9 but not-2 in human brain pericytes. Brain Res 2014; 1593: 1-8. http:// dx.doi.org/10.1016/j.brainres.2014.10.029
55. CUI J, CHEN S, ZHANG C, MENG F, WU W et al. Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebralischemia. Mol Neurodegener 2012; 7: 21. http://dx.doi.org/10.1186/1750-1326-7-21
56. CHANTRAIN CF, SHIMADA H, JODELE S, GROSHEN S, YE W et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyterecruitment. Cancer Res 2004; 64: 1675-1686. http:// dx.doi.org/10.1158/0008-5472.CAN-03-0160
57. CHANTRAIN CF, HENRIET P, JODELE S, EMONARD H, FERON O et al. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur J Cancer 2006; 42: 310-318. http://dx.doi.org/10.1016/]. eica.2005.11.010
58. JODELE S, CHANTRAIN CF, BLAVIER L, LUTZKO C, CROOKS GM et al. The contribution of bone marrow-derived cells to the tumor vasculaturein neuroblastoma is matrixmetalloproteinase-9 dependent. Cancer Res 2005; 65: 3200-3208.
59. THANABALASUNDARAM G, PIEPER C, LISCHPER M, GALLA HJ. Regulation of the blood-brain barrier integrity by pericytes via matrix metalloproteinases mediated activation of vascular endothelial growth factor in vitro. Brain Res 2010; 1347: 1-10. http://dx.doi.org/10.1016/j.brainres.2010.05.096
60. CHANG SH, KANASAKI K, GOCHEVA V, BLUM G, HARPER J et al. Vegf-a induces angiogenesis by perturbing the cathepsincysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res 2009; 69: 4537-4544. http://dx.doi. org/10.1158/0008-5472.CAN-08-4539
61. FRANCO M, ROSWALL P, CORTEZ E, HANAHAN D, PIETRAS K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011; 118: 2906-2917. http://dx.doi.org/10.1182/ blood-2011-01-331694
62. GREENBERG JI, SHIELDS DJ, BARILLAS SG, ACEVEDO LM, MURPHY E et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008; 456: 809-813. http://dx.doi.org/10.1038/nature07424
63. BANFI A, VON DEGENFELD G, GIANNI-BARRERA R, REGINATO S, MERCHANT MJ et al. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB. FASEB J 2012; 26: 2486-2497. http://dx.doi. org/10.1096/fj.11-197400
64. NASARRE P, THOMAS M, KRUSE K, HELFRICH I, WOLTER V et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensablefor later stages of tumor growth. Cancer Res 2009; 69: 1324-1333. http://dx.doi.org/10.1158/0008-5472.CAN-08-3030
65. WAKUI S, YOKOO K, MUTO T, SUZUKI Y, TAKAHASHI H et al. Localization of Ang-1,-2, Tie-2, and VEGF expression at endothelial pericyte interdigitation in rat angiogenesis. Lab Invest 2006; 86: 1172-1184. http://dx.doi.org/10.1038/ labinvest.3700476
66. KUTCHER ME, KOLYADA AY, SURKS HK, HERMAN IM. Pericyte Rho GTPase mediates both pericyte contractile phenotype and capillary endothelial growth state. Am J Pathol 2007;171: 693-701. http://dx.doi.org/10.2353/ aipath.2007.070102
67. MOTIEJUNAITE R, ARANDA J, KAZLAUSKAS A. Pericytes prevent regression of endothelial cell tubes by accelerating metabolism of lysophosphatidic acid. Microvasc Res 2014; 93: 62-71. http://dx.doi.org/10.1016/j.mvr.2014.03.003
68. LEDERLE W, LINDE N, HEUSEL J, BZYL J, WOENNE EC et al. Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. Am. J. Pathol 2010; 176: 981-994. http://dx.doi.org/10.2353/ aipath.2010.080998
69. RAZA A, FRANKLIN MJ, DUDEK AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 2010; 85: 593-598. http://dx.doi.org/10.1002/ aih.21745
70. SUN H, GUO D, SU Y, YU D, WANG Q et al. Hyperplasia of pericytes is one of the main characteristics of microvascular architecture in malignant glioma. PLoS One 2014; 9: e114246. http://dx.doi.org/10.1371/journal.pone.0114246
71. ANFUSO CD, MOTTA C, GIURDANELLA G, ARENA V, ALBERGHINA M et al. Endothelial PKCα-MAPK/ ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes?. Biochimie 2014; 99: 77-87. http://dx.doi.org/10.1016/!. biochi.2013.11.013
72. CAO Y, ZHANG ZL, ZHOU M, ELSON P, RINI B et al. Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer 2013; 119: 313-324. http://dx.doi.org/10.1002/cncr.27746
73. RIGAMONTI N, KADIOGLU E, KEKLIKOGLOU I, WYSER RMILI C, LEOW CC et al. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep 2014; 8: 696-706. http://dx.doi.org/10.1016/j.celrep.2014.06.059
74. SKULI N, MAJMUNDAR AJ, KROCK BL, MESQUITA RC, MATHEW LK et al. Endothelial HIF-2a regulates murine pathological angiogenesis and revascularization processes. J Clin Invest 2012; 122: 1427-1443. http://dx.doi.org/10.1172/ JCI57322
75. TREVI-O-VILLARREAL JH, COTANCHE DA, SEPULVEDA R, BORTONI ME, MANNEBERG O et al. Host-derived pericytes and Sca-1+ cells predominate in the MART-1-stroma fraction of experimentally induced melanoma. J Histochem Cytochem 2011; 59: 1060-1075. http://dx.doi. org/10.1369/0022155411428078
76. TRUETTNER JS, KATYSHEV V, ESEN-BILGIN N, DIETRICH WD, DORE-DUFFY P. Hypoxia alters MicroRNA expression in rat cortical pericytes. Microrna 2013; 2: 32-44. http://dx.doi.org/10.2174/2211536611302010005
77. STREMITZER S, ZHANG W, YANG D, NING Y, STINTZING S et al. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. Cancer 2015; 121: 1898-1905. http://dx.doi.org/10.1002/cncr.29259
78. MAZZIERI R, PUCCI F, MOI D, ZONARI E, RANGHETTI A et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19: 512-526. http://dx.doi.org/10.1016/_i. ccr.2011.02.005
79. WELEN K, JENNBACKEN K, TESAN T, DAMBER JE. Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts. Prostate cancer and prostatic diseases 2009; 12: 41-46. http://dx.doi.org/10.1038/ pcan.2008.33
80. COOKE VG, LEBLEU VS, KESKIN D, KHAN Z, O'CONNELL JT et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012; 21: 66-81. http://dx.doi.org/10.1016/j.ccr.2011.11.024
81. XIAN X, HÅKANSSON J, STÅHLBERG A, LINDBLOM P, BETSHOLTZ C et al. Pericytes limit tumor cell metastasis. J Clin Invest 2006; 116: 642-651. http://dx.doi.org/10.1172/lCI25705
82. LUGASSY C, PÉAULT B,WADEHRAM, KLEINMAN HK, BARNHILL RL. Could pericytic mimicry represent another type of melanoma cell plasticity with embryonic properties?. Pigment Cell Melanoma Res 2013; 26: 746-754. http://dx.doi. org/10.1111/pcmr.12120
83. LUGASSY C, WADEHRA M, LI X, CORSELLI M, AKHAVAN D et al. Pilot study on "pericytic mimicry" and potential embryonic/ stem cell properties of angiotropic melanoma cells interacting with the abluminal vascular surface. Cancer Microenviron 2013; 6: 19-29. http://dx.doi.org/10.1007/s12307-012-0128-5
84. DOMEV H, MILKOV I, ITSKOVITZ-ELDOR J, DAR A. Immunoevasive pericytes from human pluripotent stem cells preferentially modulate induction of allogeneic regulatory T cells. Stem Cells Transl Med 2014; 3: 1169-1181. http://dx.doi. org/10.5966/sctm.2014-0097
85. PIEPER C, MAREK JJ, UNTERBERG M, SCHWERDTLE T, GALLA HJ. Brain capillary pericytes contribute to the immune defense in response to cytokines or LPS in vitro. Brain Res 2014; 1550: 1-8. http://dx.doi.org/10.1016/j. brainres.2014.01.004
86. OCHS K, SAHM F, OPITZ CA, LANZ TV, OEZEN I et al. Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. J Neuroimmunol 2013; 265: 106-116. http://dx.doi.org/10.1016/j. jneuroim.2013.09.011
87. KHASRAW M, AMERATUNGA M, GROMMES C. Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials. Expert Opin Biol Ther 2014; 14: 729-740. http://dx.doi.org/10.1517/14712598.2014.898060
88. NAGY JA, CHANG SH, SHIH SC, DVORAK AM, DVORAK HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost 2010; 36: 321-331. http://dx.doi.org/10.1055/s-0030-1253454
89. ZHAO W, GUO MX, XIANG DM, ZHOU J. Effects of pericytes on the leakage of rat corneal neovascularization. Zhonghua Yi Xue Za Zhi 2013; 93: 2164-2166.
90. GOEL S, DUDA DG, XU L, MUNN LL, BOUCHER Y et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-1121. http://dx.doi. org/10.1152/physrev.00038.2010
91. CARMELIET P, JAIN RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-427. http://dx.doi. org/10.1038/nrd3455
92. AGRAWAL V, MAHARJAN S, KIM K, KIM NJ, SON J et al. Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice. Oncotarget 2014; 5: 2761-2777. http://dx.doi.org/10.18632/ oncotarget.1942
93. WEISSHARDT P, TRARBACH T, DURIG J, PAUL A, REIS H et al. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol 2012; 137: 391-401. http://dx.doi.org/10.1007/s00418-011-0898-8
94. MCCARTY MF, SOMCIO RJ, STOELTZING O, WEY J, FAN F et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007; 117: 2114-2122. http://dx.doi. org/10.1172/JCI31334
95. FALCON BL, HASHIZUME H, KOUMOUTSAKOS P, CHOU J, BREADY JV et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumorblood vessels. Am J Pathol 2009; 175: 2159-2170. http://dx.doi.org/10.2353/ajpath.2009.090391
96. PAULSSON J, SJOBLOM T, MICKE P, PONTEN F, LANDBERG G et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009; 175: 334-341. http:// dx.doi.org/10.2353/ajpath.2009.081030
97. HAGGLOF C, HAMMARSTEN P, JOSEFSSON A, STATTIN P, PAULSSON J et al. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancersurvival. PLoS One 2010; 5: e10747. http:// dx.doi.org/10.1371/journal.pone.0010747
98. CHUTE JP, HIMBURG HA. Imatinib tackles lymphoma via the PDGFRβ+ pericyte. Blood 2013; 121: 5107-5108. http:// dx.doi.org/10.1182/blood-2013-05-501205
99. TSAO AS, LIU S, FUJIMOTO J, WISTUBA II, LEE JJ et al. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and headand neck squamous cell carcinoma. J Thorac Oncol 2011; 6: 2104-2111. http://dx.doi.org/10.1097/JTO.0b013e31822e7256
100. RAYMOND E, BRANDES AA, DITTRICH C, FUMOLEAU P, COUDERT B et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008; 26: 4659-4665. http:// dx.doi.org/10.1200/JCO.2008.16.9235
101. TAEGER J, MOSER C, HELLERBRAND C, MYCIELSKA ME, GLOCKZIN G et al. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells,endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 2011; 10: 2157-2167. http://dx.doi. org/10.1158/1535-7163.MCT-11-0312
102. SENNINO B. Two is better than one: benefits of VEGF and PDGF inhibition in ovarian cancer. Cancer Biol Ther 2010; 9: 183-185. http://dx.doi.org/10.4161/cbt.9.3.11117
103. KUHNERT F, TAM BY, SENNINO B, GRAY JT, YUAN J et al. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci USA 2008; 105: 10185-10190. http://dx.doi.org/10.1073/pnas.0803194105
104. ABOU-ALFA GK, JOHNSON P, KNOX JJ, CAPANU M, DAVIDENKO I et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: arandomized trial. JAMA 2010; 304: 2154-2160. http://dx.doi.org/10.1001/jama.2010.1672
105. RAYMOND E, DAHAN L, RAOUL JL, BANG YJ, BORBATH I et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513. http:// dx.doi.org/10.1056/NEJMoa1003825
106. KOEBERLE D, MONTEMURRO M, SAMARAS P, MAJNO P, SIMCOCK M et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for ClinicalCancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK77/06). Oncologist 2010; 15: 285-292. http://dx.doi. org/10.1634/theoncologist.2009-0316
107. GROTHEY A, VAN CUTSEM E, SOBRERO A, SIENA S, FALCONE A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international,multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312. http://dx.doi. org/10.1016/S0140-6736(12)61900-X
108. NISANCIOGLU MH, BETSHOLTZ C, GENOVE G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res 2010; 70: 5109-5115. http:// dx.doi.org/10.1158/0008-5472.CAN-09-4245
109. WANG S, CAO C, CHEN Z, BANKAITIS V, TZIMA E et al. Pericytes regulate vascular basement membrane remodeling and govern neutrophil extravasation during inflammation. PLoS One 2012; 7: e45499. http://dx.doi.org/10.1371/journal. pone.0045499
110. RHETT JM, JOURDAN J, GOURDIE RG. Connexin 43 connexon to gap iunction transition is regulated by zonula occludens-1. Mol Biol Cell 2011; 22: 1516-1528. http://dx.doi. org/10.1091/mbc.E10-06-0548
111. MCGUIRE PG, RANGASAMY S, MAESTAS J, DAS A. Pericyte derived sphinogosine 1-phosphate induces the expression of adhesion proteins and modulates the retinal endothelial cell barrier. Arterioscler Thromb Vasc Biol 2011; 31: e107-e115. http://dx.doi.org/10.1161/ATVBAHA.111.235408
112. JO DH, KIM JH, HEO JI, KIM JH, CHO CH. Interaction between pericytes and endothelial cells leads to formation of tight junction in hyaloid vessels. Mol Cells 2013; 36: 465-471. http://dx.doi.org/10.1007/s10059-013-0228-1
113. SHIMIZU F, SANO Y, ABE MA, MAEDA T, OHTSUKI S et al. Peripheral nerve pericytes modify the blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors. J Cell Physiol 2011; 226: 255-266. http://dx.doi.org/10.1002/jcp.22337
114. RUAN J, LUO M, WANG C, FAN L, YANG SN et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 2013; 121: 5192-5202. http://dx.doi.org/10.1182/ blood-2013-03-490763
115. GUAN YY, LUAN X, XU JR, LIU YR, LU Q et al. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis. Biomaterials 2014; 35: 3060-3070. http://dx.doi. org/10.1016/j.biomaterials.2013.12.027